Corbus Pharmaceuticals Holdings, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging -2.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.30 | $-1.81 | -39.2% | Miss | |
| Q1 FY26 | $-1.26 | $-1.23 | +2.4% | Beat | |
| Q4 FY25 | $-1.78 | $-1.25 | +29.8% | Beat |
Back to CRBP overview · CRBP holders · CRBP KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.